$AGIO News

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology - Slideshow

Agios Acquires Global Rights to Experimental Blood Disorder Drug From South Korea's Oscotec

B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40

Agios Pharma Says It Will Not Advance Tebapivat, Next-Gen Oral Pyruvate Kinase Activator, In Lower-Risk Myelodysplastic Syndromes As Phase 2b Trial Results Did Not Meet Predefined Threshold To Support Further Development In LR-MDS

Agios Pharmaceuticals Announces EU Marketing Authorization For PYRUKYND In Adults For Treatment Of Anemia

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios Pharmaceuticals Submits Supplemental New Drug Application To FDA Seeking Accelerated Approval Of Oral Pyruvate Kinase Activator Mitapivat; To Also Present New Data On Mitapivat At 31st European Hematology Association Congress

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)

AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum

Agios Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $36

Agios Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript

Agios Pharmaceuticals Q1 Earnings Call Highlights

Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2026 Earnings Beat Drives Stock Rally

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Agios Pharmaceuticals Q1 EPS $(1.69) Beats $(1.79) Estimate, Sales $20.746M Beat $13.646M Estimate

BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)

Do Upbeat EPS Revisions Before Earnings Quietly Reframe Agios Pharmaceuticals’ (AGIO) Risk‑Reward Profile?